Andrew L Gilman,
Kirk R Schultz,
Frederick D Goldman,
George E Sale,
Mark D Krailo,
Zhengjia Chen,
Bryan Langholz,
David A Jacobsohn,
Ka-Wah Chan,
Robin E Ryan, Michael Kellick,
Steven M Neudorf,
Kamar Godder,
Eric S Sandler,
Indira Sahdev,
Stephan A Grupp,
Jean E Sanders,
Donna A Wall
[show abstract]
[hide abstract]
ABSTRACT: The Children's Oncology Group conducted a multicenter Phase III trial for chronic graft-versus-host disease (cGVHD). The double-blind, placebo-controlled, randomized study evaluated hydroxychloroquine added to standard therapy for children with newly diagnosed cGVHD. The study also used a novel grading and response scoring system and evaluated clinical laboratory correlates of cGVHD. The primary endpoint was complete response (CR) after 9 months of therapy. Fifty-four patients (27 on each arm) were enrolled before closure because of slow accrual. The CR rate was 28% in the hydroxychloroquine arm versus 33% in the placebo arm (odds ratio [OR] = 0.77, 95% confidence interval [CI]: 0.20-2.93, P = .75) for 42 evaluable patients. For 41 patients with severity assessment at enrollment, 20 (49%) were severe and 18 (44%) moderate according to the National Institutes of Health Consensus Conference global scoring system. The CR rate was 15% for severe cGVHD and 44% for moderate cGVHD (OR = 0.24, 95% CI: 0.05-1.06, P = .07). Although the study could not resolve the primary question, it provided important information for future cGVHD study design in this population.
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 05/2011; 18(1):84-91. · 3.15 Impact Factor
